From Wikipedia, the free encyclopedia
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010 , it is undergoing Phase II/III clinical trials.
- ^ Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial agents and chemotherapy 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668. PMID 19380597.
- ^ ClinicalTrials.gov NCT00646399 Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis